11月18日，艾德生物盘中下跌2.02%，截至14:00，报22.83元/股，成交1.17亿元，换手率1.31%，总市值 89.39亿元。 资金流向方面，主力资金净流出1487.12万元，特大单买入115.10万元，占比0.98%，卖出984.08万元， 占比8.38%；大单买入2566.71万元，占比21.86%，卖出3184.84万元，占比27.12%。 艾德生物今年以来股价涨1.47%，近5个交易日跌2.48%，近20日涨0.13%，近60日跌5.74%。 资料显示，厦门艾德生物医药科技股份有限公司位于福建省厦门市海沧区鼎山路39号，成立日期2008年 2月21日，上市日期2017年8月2日，公司主营业务涉及肿瘤精准医疗分子诊断产品的研发、生产及销售, 并提供相关的检测服务。主营业务收入构成为：检测试剂83.43%，药物临床研究服务9.84%，检测服务 5.61%，其他(补充)1.12%。 艾德生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：小盘、基因测序、增持 回购、融资融券、医疗器械等。 截至9月30日，艾德生物股东户数2.66万，较上期增加5.23%；人均流通股14628股，较 ...

艾德生物成立于2008年2月21日，于2017年8月2日在深圳证券交易所上市，注册及办公地址均为福建省厦 门市。它是国内肿瘤精准医疗分子诊断领域的领先企业，拥有全流程技术平台和丰富的产品管线。 艾德生物主营业务为肿瘤精准医疗分子诊断产品的研发、生产及销售，并提供相关的检测服务，所属申万 行业为医药生物 - 医疗器械 - 体外诊断，涉及基因测序、体外诊断、精准医疗等概念板块。 经营业绩：营收行业第12，净利润行业第5 2025年三季度，艾德生物实现营业收入8.66亿元，在行业39家公司中排名第12。行业第一名新产业营收 34.28亿元，第二名安图生物营收31.27亿元，行业平均数为7.08亿元，中位数为3.3亿元。主营业务构成 中，检测试剂4.83亿元占比83.43%，药物临床研究服务5698.83万元占比9.84%，检测服务3250.49万元占比 5.61%，其他（补充）651.67万元占比1.12%。当期净利润为2.63亿元，行业排名第5，行业第一名九安医疗 净利润15.88亿元，第二名新产业净利润12.05亿元，行业平均数为1.1亿元，中位数为2618.92万元。 资产负债率低于同业平均，毛利率高于同业平 ...

Core Viewpoint - The company, Adebiotech, announced a share buyback plan with a total amount between 100 million and 200 million yuan, with a maximum buyback price of 34.50 yuan per share, which is 48.90% higher than the current price of 23.17 yuan [1] Group 1: Financial Performance - As of September 30, the company reported a revenue of 866 million yuan for the first nine months of 2025, representing a year-on-year growth of 2.08% [2] - The net profit attributable to the parent company for the same period was 263 million yuan, showing a year-on-year increase of 15.50% [2] - Cumulatively, the company has distributed 421 million yuan in dividends since its A-share listing, with 232 million yuan distributed over the last three years [3] Group 2: Shareholder Information - The number of shareholders increased by 5.23% to 26,600 as of September 30 [2] - The average number of circulating shares per shareholder decreased by 4.97% to 14,628 shares [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.39 million shares, an increase of 3.72 million shares from the previous period [3]

Core Viewpoint - The stock of Aide Biological experienced a decline of 2.03% on September 12, with a current price of 23.66 CNY per share and a total market capitalization of 9.264 billion CNY, indicating a mixed performance in recent trading sessions [1]. Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, representing a year-on-year growth of 6.69%, and a net profit attributable to shareholders of 189 million CNY, which is a 31.41% increase compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 421 million CNY, with 232 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 5.41% to 25,300, while the average circulating shares per person decreased by 5.13% to 15,393 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.6706 million shares, a decrease of 3.5159 million shares from the previous period [3]. - New entrants among the top ten circulating shareholders include Hua Bao Zhong Zheng Medical ETF, holding 9.0366 million shares [3]. Stock Performance - Year-to-date, Aide Biological's stock price has increased by 5.16%, but it has seen a decline of 4.56% over the last five trading days and a slight decrease of 1.05% over the past 20 days [1]. - The stock has shown a more favorable performance over the last 60 days, with an increase of 13.15% [1]. Business Overview - Aide Biological, established on February 21, 2008, and listed on August 2, 2017, specializes in the research, production, and sales of molecular diagnostic products for precision oncology, along with related testing services [1]. - The company's revenue composition includes 83.43% from testing reagents, 9.84% from clinical research services, 5.61% from testing services, and 1.12% from other sources [1].

Financial Performance - The company reported a revenue of RMB 3.25 billion for the six months ending June 30, 2025, representing a year-on-year decline of 3.2% [1] - Profit attributable to shareholders decreased by 22.2% to RMB 383 million during the same period, with earnings per share at RMB 0.45 [1] - The board has decided not to declare any interim dividend for the six months ending June 30, 2025 [1] Clinical Research Projects - As of June 30, 2025, the company has 409 clinical research projects ongoing domestically and 237 projects abroad [1] - Among the international projects, 194 are conducting single-region clinical trials primarily in South Korea, Australia, Southeast Asia, Europe, and the United States [1] - The company is also involved in multi-region clinical trials across the Asia-Pacific, North America, Europe, and Africa, covering therapeutic areas such as oncology, respiratory, cardiovascular, endocrine, rheumatology, infectious diseases, rare diseases, and vaccines [1] Future Strategy - The company aims to embrace regulatory changes, technological innovations, and global expansion to enhance its integrated clinical research service platform [2] - Plans include establishing dedicated business teams for specific therapeutic areas to expand client relationships with multinational and large domestic pharmaceutical companies [2] - The company seeks sustainable growth and potential acquisitions to enhance its business and operational capabilities in the U.S. and Europe, while strengthening collaborative relationships within the industry to solidify its domestic market position and increase global market share [2]

Core Insights - The company achieved steady revenue growth in the first half of 2024, with revenue of 579 million (+6.7%) and net profit attributable to shareholders of 189 million (+31.4%) [1] - The company maintains a comprehensive companion diagnostic product system, supporting both targeted and immunotherapy [1][3] - The company is a leader in the field of tumor precision diagnosis and is expected to benefit from the growth in precision treatment for tumors [3] Revenue and Profit Analysis - In Q2 2024, the company reported revenue of 307 million (-0.8%), but a quarter-on-quarter growth of 13% [1] - The net profit for Q2 was 99 million (+23.7%), with a quarter-on-quarter increase of 9% [1] - The adjusted net profit for Q2 was 98 million (+16.7%), indicating strong year-on-year profit growth [1] Business Segment Performance - Revenue from diagnostic reagents in the first half of 2024 was 483 million (+7.9%), with a gross margin of 90.7% [1] - The testing services segment generated revenue of 33 million (+0.9%), with a gross margin of 48.7% [1] - The drug clinical research services segment saw revenue of 57 million (-5%), with a gross margin of 53.1% [2] Cost and Margin Analysis - The overall gross margin for the first half of 2024 was 84.0% (-1.1 percentage points) [3] - Sales expense ratio decreased to 25.7% (-3.8 percentage points), and R&D expense ratio decreased to 15.6% (-3.9 percentage points) [3] - The net profit margin increased significantly, with a net profit margin of 32.6%, up 6.1 percentage points year-on-year [3] Cash Flow and Future Outlook - The operating cash flow net amount for the first half of 2024 was 171 million (+22.6%), maintaining a healthy ratio of operating cash flow to net profit [3] - The company maintains profit forecasts for 2025-2027, with expected net profits of 317 million, 382 million, and 451 million, representing year-on-year growth of 24.4%, 20.5%, and 18.1% respectively [3]

近期艾德生物（300685）发布2025年中报，证券之星财报模型分析如下： 营收与利润 艾德生物发布的2025年中报显示，截至报告期末，公司营业总收入为5.79亿元，同比上升6.69%。归母 净利润为1.89亿元，同比上升31.41%，扣非净利润为1.85亿元，同比上升39.97%。这表明公司在报告期 内实现了较为稳健的营收增长，且净利润显著提升。 按单季度数据看，第二季度营业总收入为3.07亿元，同比下降0.8%，但第二季度归母净利润为9856.56 万元，同比上升23.74%，扣非净利润为9757.26万元，同比上升30.03%。尽管第二季度营收略有下降， 但净利润仍保持较高增速。 每股净资产为4.82元，同比增加8.83%；每股经营性现金流为0.44元，同比增加24.78%；每股收益为0.48 元，同比增加33.33%。 主营业务构成 公司主营业务收入主要来自检测试剂、药物临床研究服务、检测服务及其他业务。其中，检测试剂收入 为4.83亿元，占主营收入的83.43%，毛利率高达90.72%；药物临床研究服务收入为5698.83万元，占 9.84%，毛利率为53.14%；检测服务收入为3250.49万元， ...

Group 1 - The core viewpoint of the news is that Aide Biological has a current PE ratio of 34.19, which is the lowest in 106 days, and its market capitalization is 9.612 billion yuan [1] - The average PE ratio in the medical device industry is 55.28, with a median of 38.06, placing Aide Biological at the 68th position in the industry ranking [1] - As of the 2025 semi-annual report, there are 8 institutions holding shares in Aide Biological, all of which are funds, with a total holding of 1.3993 million shares valued at 30 million yuan [1] Group 2 - Aide Biological's main business includes tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The latest performance report shows that for the first half of 2025, the company achieved operating revenue of 579 million yuan, a year-on-year increase of 6.69%, and a net profit of 189 million yuan, a year-on-year increase of 31.41%, with a gross profit margin of 84.00% [1]

Company Overview - Xiamen Aide Biological Technology Co., Ltd. specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The main products include testing reagents, testing services, and drug clinical research services [1] Financial Performance - For Q1 2025, the company reported revenue of 272 million yuan, representing a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.47 million yuan, showing a year-on-year growth of 40.92% [1] - The sales gross margin stood at 83.48% [1] Market Position - As of July 25, the company's stock closed at 24.13 yuan, with a 1.00% increase, and a rolling price-to-earnings (PE) ratio of 33.61, marking a new low in 95 days [1] - The total market capitalization is 9.448 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 55.41, with a median of 37.94, placing Aide Biological at the 68th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, there are 8 institutions holding shares in Aide Biological, all of which are funds, with a total holding of 1.3993 million shares valued at 3 million yuan [1]

7月23日，艾德生物今日收盘23.66元，上涨1.28%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到32.95倍，创86天以来新低，总市值92.64亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.52倍，行业中值37.14倍，艾德生物排 名第69位。 资金流向方面，7月23日，艾德生物主力资金净流入952.49万元，近5日总体呈流出状态，5日共流出 4540.36万元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.72亿元，同比16.63%；净利润9047.18万元， 同比40.92%，销售毛利率83.48%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13艾德生物32.9536.354.8392.64亿行业平均 53.5248.844.67111.58亿行业中值37.1437.112.5651.72亿1九安医疗10.9411.060.86184.59亿2英科医疗 12.7713.771.14201.84亿3新华医疗15.2014.091.2497.43亿4奥美医疗15.9515.631.6457.63亿5山东药玻 15.9516.001.8315 ...